Two phase 3 trials suggest that a 16 week treatment with a drug called lebrikizumab was effective in adults and adolescents with moderate to severe dermatitis, according to […]
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare news and e-journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our email journals and publications.
